Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New drug class for overactive bladder launched


A once-daily drug has been launched in the UK for the symptoms of overactive bladder.

Mirabegron (Betmigatm) is the first of a new drug class, known as oral β3-adrenoceptor agonists, which work in a different way to antimuscarinics.

Mirabegron causes relaxation of the bladder muscle during the storage phase of the micturition cycle, improving the storage capacity of the bladder without inhibiting bladder voiding, according to its manufacturer Astellas Pharma.

The drug was launched on 27 february, prompting the National Institute for Health and Clinical Excellence to describe it as a “welcome alternative to current available treatments”.

It announced on 1 March that it had begun a consultation on draft guidance, which provisionally recommended the use of mirabegron for the treatment of overactive bladder syndrome for patients in whom antimuscarinic drugs are not suitable.

NICE chief executiveSir Andrew Dillon said: “Offering mirabegron as an option for treatment, with clear advice about its potential benefits and side effects will help improve quality of life for people living with this distressing condition.”

Consultees, including the manufacturer, healthcare professionals and members of the public are now able to comment on the preliminary NICE recommendations for the use of mirabegron.

The recommendations will be available for public consultation from 1-22 March 2013. Comments received during the consultation will be fully considered by the committee and following this meeting the next draft guidance will be issued, NICE said.


Readers' comments (3)

  • Gary Musgrove

    This is great news. Just what the overactive bladder has been waiting for. Gives a little more choice to what we currently have.

    Unsuitable or offensive? Report this comment

  • Beta -3 receptor agonists like Mirabegron should never be used with any patients with atrial fibrillation or any other arrythmias.
    It would be interesting to see whether mirabegron can promote weight loss in OAB patients who are also obese because there is theoretical evidence that beta-3 agonists can act as selective metabolism stimulators.
    Patrick Movsessian

    Unsuitable or offensive? Report this comment

  • it is not new but thanks Patrick Movessian for the warning.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.